Dec, 2005
Intravenous immunoglobulin and atherosclerosis
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- ,
- ,
- ,
- Volume
- 29
- Number
- 3
- First page
- 311
- Last page
- 319
- Language
- English
- Publishing type
- Research paper (scientific journal)
- Publisher
- HUMANA PRESS INC
Several inflammatory and immunological factors have been established as important contributors to atherogenesis. Among these, oxidized low-density lipoprotein (oxLDL) play a central role in the initiation and progression of atherosclerotic lesions. In atherosclerotic lesions, oxLDL was also found to co-localize with beta(2)-glycoprotein I (beta(2)-GPI). Immunoglobulin (Ig)G autoantibodies against beta(2)-GPI complexes with oxLDL are pro-atherogenic because they increase uptake of the complexes by macrophages. In contrast, IgM natural anti-oxLDL antibodies derived from atherosclerosis-prone apolipoprotein E (ApoE) deficient mice reduced incidence of atherosclerosis. Such anti-oxLDL antibodies have been found in humans, and the accumulating evidences seem to support the idea that anti-oxLDL antibodies have a protective role for atherogenesis. Intravenous immunoglobulins (IVIgs) contain natural anti-oxLDL antibodies and infusion of IVIg into ApoE-deficient mice has been reported to decrease atherosclerosis. The anti-atherogenic property of IVIg may be derived from non-antigen-specific antibody binding to FC gamma receptors, which blocks foam cell formation of macrophages. Several other possible mechanisms are also discussed.
- Link information
- ID information
-
- ISSN : 1080-0549
- Web of Science ID : WOS:000235967400018